Jihong Chen Selected Research

patisiran

1/2021	Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
9/2020	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
3/2020	Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
3/2020	Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
1/2020	A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
1/2019	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
1/2019	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
1/2018	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
9/2017	Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jihong Chen Research Topics

Disease

8	Polyneuropathies (Polyneuropathy) 01/2021 - 09/2017
8	Amyloidosis 01/2021 - 09/2017
4	Neoplasms (Cancer) 01/2021 - 12/2006
2	Hyperlipidemias (Hyperlipidemia) 06/2022 - 04/2022
2	Body Weight (Weight, Body) 11/2020 - 01/2018
2	Diabetic Neuropathies (Diabetic Neuropathy) 09/2020 - 09/2017
2	Chronic Renal Insufficiency 01/2020 - 01/2020
2	Transthyretin-Related Hereditary Amyloidosis 01/2019 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2017 - 01/2017
2	Multiple Organ Failure (MODS) 11/2015 - 12/2012
2	Epilepsy (Aura) 11/2008 - 01/2005
1	Fatty Liver 06/2022
1	Hypercholesterolemia 04/2022
1	Poisoning 01/2022
1	Thrombosis (Thrombus) 01/2022
1	Acute Lung Injury 01/2022
1	Muscular Dystrophies (Muscular Dystrophy) 01/2022
1	Hyperplasia 01/2022
1	Inflammation (Inflammations) 01/2022
1	Pathologic Constriction (Stenosis) 01/2022
1	Arteriovenous Fistula 01/2022
1	Rheumatoid Arthritis 01/2021
1	Acute Intermittent Porphyria (Porphyria, Acute) 11/2020
1	Porphyrias (Porphyria) 11/2020
1	Pain (Aches) 11/2020
1	Injection Site Reaction 11/2020
1	Nasopharyngeal Carcinoma 08/2020
1	Orthostatic Intolerance 03/2020
1	Flushing 01/2020
1	Proteinuria 01/2020
1	Cardiomyopathies (Cardiomyopathy) 01/2019
1	Disease Progression 01/2019
1	Ovarian Epithelial Carcinoma 01/2018
1	Ovarian Neoplasms (Ovarian Cancer) 01/2018
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Colorectal Neoplasms (Colorectal Cancer) 10/2016
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2016

Drug/Important Bio-Agent (IBA)

9	patisiranIBA 01/2021 - 09/2017
7	Prealbumin (Transthyretin)IBA 01/2021 - 01/2019
4	3- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA 01/2018 - 04/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 02/2016
3	Valproic Acid (Depakote)FDA LinkGeneric 11/2008 - 01/2005
3	Histone Deacetylase InhibitorsIBA 11/2008 - 01/2005
2	LDL CholesterolIBA 06/2022 - 04/2022
2	CholesterolIBA 06/2022 - 04/2022
2	gamma-oryzanolIBA 06/2022 - 04/2022
2	oxidized low density lipoproteinIBA 06/2022 - 04/2022
2	Triglycerides (Triacylglycerol)IBA 06/2022 - 04/2022
2	Bexarotene (LGD1069)FDA Link 01/2021 - 02/2016
2	CreatinineIBA 11/2020 - 01/2020
2	Insulin ReceptorIBA 01/2018 - 04/2015
2	PlatinumIBA 01/2018 - 09/2017
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2017 - 01/2017
1	Amino Acids FDA Link 06/2022
1	Tyrosine (L-Tyrosine)FDA Link 06/2022
1	HDL CholesterolIBA 04/2022
1	LipidsIBA 04/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022
1	ParaquatIBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	PPAR gammaIBA 01/2022
1	Heme Oxygenase-1IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Dystroglycans (Dystroglycan)IBA 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	HLA-DQB1 antigen (HLA DQB1)IBA 01/2021
1	HLA-DRB1 Chains (HLA DRB1)IBA 01/2021
1	InotersenIBA 01/2021
1	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2021
1	MicroRNAs (MicroRNA)IBA 01/2021
1	PorphobilinogenIBA 11/2020
1	givosiranIBA 11/2020
1	Hemin (Panhematin)FDA Link 11/2020
1	Transaminases (Aminotransferases)IBA 11/2020
1	Acute Hepatic PorphyriaIBA 11/2020
1	AntioxidantsIBA 10/2020
1	Selenoproteins (Selenoprotein)IBA 10/2020
1	Thioredoxin-Disulfide ReductaseIBA 10/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Insulin (Novolin)FDA Link 01/2018
1	insulin receptor tyrosine kinaseIBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	ErbB Receptors (EGF Receptor)IBA 01/2017
1	Tyrosine Kinase InhibitorsIBA 01/2017
1	Bevacizumab (Avastin)FDA Link 10/2016
1	tivozanibIBA 10/2016
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 10/2016
1	Antineoplastic Agents (Antineoplastics)IBA 10/2016
1	LipopolysaccharidesIBA 11/2015
1	AntigensIBA 11/2015

Therapy/Procedure

7	Therapeutics 01/2021 - 01/2005
6	RNAi Therapeutics 11/2020 - 09/2017
3	Drug Therapy (Chemotherapy) 09/2017 - 04/2015
2	Chinese Traditional Medicine (Traditional Chinese Medicine) 01/2020 - 01/2020
1	Renal Dialysis (Hemodialysis) 01/2022
1	Intravenous Administration 11/2020
1	Radiotherapy 08/2020